Home / Business and Economy / US Patent Bolsters TempraMed's Smart Cap Tech
US Patent Bolsters TempraMed's Smart Cap Tech
10 Nov
Summary
- US patent granted September 29, 2026, protects VIVI Cap Smart innovations.
- Company now holds 39 granted patents globally for its technology.
- VIVI Cap Smart is pen-agnostic, enhancing medication management flexibility.
TempraMed Technologies Ltd. announced a major milestone with the formal grant of its U.S. patent on September 29, 2026. This patent, numbered 12,746,342, covers key aspects of the innovative VIVI Cap Smart™ device, designed for storing temperature-sensitive medications.
The VIVI Cap Smart™ features a proprietary thermal-insulation and smart-monitoring architecture, making it adaptable for various injection pens. This pen-agnostic design positions the platform at the intersection of home health, smart refrigeration, and connected medical devices.
This U.S. patent grant significantly strengthens TempraMed's global intellectual property portfolio, which now includes 39 granted patents and registered designs. The company's products are now available across McKesson Medical-Surgical's U.S. B2B network and online through Amazon and Walmart.
CEO Ron Nagar highlighted the U.S. market's importance, stating the patent secures protection for core innovations and supports the expansion of their product portfolio. The pen-agnostic VIVI Cap Smart™ and VIVI Med platforms aim to provide reliable temperature control for various injection devices.
